Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lower-Tier Hospitals Will See More Medical Device Growth In 2013: Citi Hospital Survey

This article was originally published in PharmAsia News

Executive Summary

Spending on new medical equipment by top-tier hospitals in China is expected to ease in 2013, but still show double-digit growth with multinationals like General Electric competing with domestic firms led by Mindray Medical.

You may also be interested in...



China's Top Device Maker Mindray Enters Critical Care Market; Sees Boosts From Color Ultrasound Devices

Despite a negative impact from political unrest in the Middle East, China's leading medical device maker Mindray Medical International is steaming ahead with solid first quarter growth in both international and Chinese domestic markets. That growth was driven largely by a continued stronghold in its low- to mid-end device market, as well as an emerging footprint in the lucrative high-end segment with its color ultrasound devices

Philips Acquires Shanghai Apex, Targets Low-End Ultrasound Market In Wake Of China Healthcare Reform

SHANGHAI - Amsterdam-based Royal Philips Electronics has acquired Shanghai Apex, an ultrasound transducer provider in China, to expand Philips' low-end ultrasound product line to take advantage of the growing device market expected from China's ongoing healthcare reforms, the company announced July 28

CROs at risk from China's new inventor regulation?

China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel